Blinatumomab - Biologic Drug Details

Summary for blinatumomab

Tradenames:	1
High Confidence Patents:	4
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for blinatumomab

Recent Clinical Trials for blinatumomab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Syndax Pharmaceuticals	PHASE1
Dana-Farber Cancer Institute	PHASE2
University of Chicago	PHASE1

See all blinatumomab clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for blinatumomab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for blinatumomab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557	10,000,574	2024-11-26	DrugPatentWatch analysis and company disclosures
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557	10,047,163	2034-02-07	DrugPatentWatch analysis and company disclosures
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557	10,071,158	2034-04-07	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for blinatumomab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557	10,047,163	2034-02-07	Patent claims search
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557	10,100,034	2037-07-25	Patent claims search
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557	10,111,968	2036-08-10	Patent claims search

International Patents for blinatumomab

Country	Patent Number	Estimated Expiration
European Patent Office	1976886
World Intellectual Property Organization (WIPO)	2016179123
Israel	138857

Supplementary Protection Certificates for blinatumomab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CR 2016 00020	Denmark		PRODUCT NAME: BLINATUMOMAB; REG. NO/DATE: EU/1/15/1047 20151125
C 2016 013	Romania		PRODUCT NAME: BLINATUMOMAB; NATIONAL AUTHORISATION NUMBER: EU/1/15/1047; DATE OF NATIONAL AUTHORISATFIRST AUTHORISATION IN EEA: 20151123 ION: 20151123; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1047; DATE OF
2016/021	Ireland		PRODUCT NAME: BLINATUMOMAB; REGISTRATION NO/DATE: EU/1/15/1047 20151123

Market Dynamics and Financial Trajectory for Blinatumomab

Last updated: March 13, 2026

What are the key factors influencing the market for blinatumomab?

Blinatumomab is an immune-oncology bispecific T-cell engager approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Its market is driven by several factors:

• Regulatory approvals: Blinatumomab received FDA approval in 2014 for adults and in 2018 for pediatric patients with relapsed/refractory B-cell ALL, expanding its access.
• Unmet clinical needs: Limited options for relapsed/refractory ALL boost demand.
• Treatment paradigm shifts: The rise of immunotherapies, including CAR-T cell therapies, impacts the competitive landscape.
• Pricing and reimbursement: High costs (~$178,000 per treatment course in the US) influence adoption.
• Manufacturing complexities: The drug's continuous infusion and specialized handling challenge widespread administration.
• Orphan drug designation: Grants market exclusivity duration and tax incentives, affecting long-term market control.

How does the current market size compare across regions?

The global blinatumomab market was valued at approximately USD 1.3 billion in 2022. Key regional contributions include:

Region	Market Share (2022)	Key Drivers
North America	60%	High prevalence of ALL, advanced healthcare infrastructure, insurance coverage for high-cost therapies
Europe	20%	Approval in multiple countries, growing clinical adoption
Asia-Pacific	10%	Increasing oncology screening, emerging healthcare systems, off-label use in some indications
Rest of World	10%	Limited access, approval delays, cost barriers

Market growth is projected at a Compound Annual Growth Rate (CAGR) of approximately 10% from 2023 to 2028, driven mainly by increased adoption in Europe and Asia-Pacific regions.

What are the primary drivers and inhibitors of growth?

Drivers:

• Efficacy in treatment-resistant cases: Blinatumomab demonstrates durable responses in refractory ALL.
• Expanded indications: Recently tested in minimal residual disease (MRD) positivity, with potential approval as a maintenance therapy.
• Pipeline developments: New formulations, combination therapies, and bi-specific constructs could extend utility.
• Reimbursement expansions: Increasing insurance coverage reduces patient out-of-pocket costs.

Inhibitors:

• Competition from CAR-T therapies: Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) compete in similar indications.
• Administration complexities: Continuous infusion for 28 days complicates outpatient use.
• Adverse effects: Cytokine release syndrome (CRS) and neurotoxicity necessitate specialized monitoring.
• Pricing pressures: Payer resistance to high drug costs constrains revenue growth.

How does the financial trajectory project over the next five years?

Projected revenues for blinatumomab are expected to reach USD 2.2 billion in 2028, reflecting:

• Market penetration: Anticipated increase in new patient diagnoses and expanded indications.

• Pricing trends: Slight adjustments due to payer negotiations, with continued high-per-unit costs.

• Generic and biosimilar presence: No biosimilar exists yet, but patent expiration around 2028-2030 could change the landscape.

• Market share shifts: Competition from CAR-T therapies could capture a significant portion of the market, especially among younger patients.

What are the key financial risks and opportunities?

Risks:

• Patent expiration: Loss of exclusivity could reduce profits.
• Regulatory delays: New indications or formulations may face approval hurdles.
• Market saturation: Limited eligible patient population capacity constrains growth.

Opportunities:

• Combination therapies: Partnering with other immunotherapies can expand application.
• New indications: Investigation into solid tumors and MRD settings may extend revenue streams.
• Geographic expansion: Entry into emerging markets through partnerships and licensing.

Final analysis

Blinatumomab remains a key asset in refractory ALL management, with high revenue potential, especially if pipeline progress and geographic access improve. The competitive landscape, especially with CAR-T therapies, poses challenges that could influence future market share and profitability.

---

Key Takeaways

• The global market for blinatumomab was valued at USD 1.3 billion in 2022, with a projected CAGR of 10% up to 2028.
• North America commands the majority of revenue, driven by clinical adoption and healthcare infrastructure.
• Market growth hinges on expanding indications, pipeline developments, and acceptance of combination approaches.
• Competition from CAR-T therapies and administration complexity are primary barriers.
• Patent expirations around 2028-2030 could significantly impact market exclusivity.

FAQs

1. How does blinatumomab compare to CAR-T therapies?
Blinatumomab is an off-the-shelf immunotherapy administered as a continuous infusion, with fewer logistical demands. CAR-T therapies require cell collection, manufacturing, and have longer hospitalization, but often provide longer-lasting remissions in some patients.

2. What are the main challenges in expanding blinatumomab's use?
The need for specialized infusion centers, risk of cytokine release syndrome, high cost, and competition from emerging immunotherapies limit broader application.

3. Are new formulations of blinatumomab in development?
Yes, some research focuses on subcutaneous delivery and extended-release formulations to improve convenience and compliance.

4. What are future pipeline candidates related to blinatumomab?
Clinical trials are exploring combination therapies with checkpoint inhibitors and other immune modulators, as well as applications in minimizing residual disease.

5. What impact could biosimilars have?
If biosimilars enter the market post-patent expiry, they could reduce prices and improve access but may also decrease manufacturer revenues.

---

References

[1] MarketWatch. (2022). "Blinatumomab market size and forecast."
[2] U.S. Food and Drug Administration. (2014). "FDA approval for Blinatumomab."
[3] Thomson Reuters. (2022). "Biotech pipeline and licensing insights."
[4] Evaluate Pharma. (2023). "Immunotherapy market report."